de TRR179 TRR179 goes Podcast Fri, 19 Jun 2026 08:19:29 +0000 Fri, 19 Jun 2026 10:19:29 +0200 podcaster.de Feedarator 6.2 (https://app.podcaster.de) https://fitg8h.podcaster.de/ katrin.woll@med.uni-heidelberg.de (TRR179) by TRR179 Podcast TRR179 TRR179 no false TRR179 katrin.woll@med.uni-heidelberg.de TRR179 goes Podcast TRR179 goes Podcast episodic TRR179 - New avenues for vaccines and cancer immunotherapies Chronic infections cause long-term changes in key immune cells. T-helper cells suppress their immune function to ensure their survival.

T-helper cells, scientifically known as CD4⁺ T cells, control key processes in our immune system. They detect signs of pathogens and relay signals to other immune cells. In this way, they help B cells produce antibodies and support T killer cells in fighting infected cells. Researchers at the Medical Center – University of Freiburg have now investigated how these immune cells change under prolonged stress during chronic infections. Using chronic hepatitis C infection as an example, the team demonstrated that T helper cells shift their focus: they regulate the immune response less vigorously in order to ensure their own survival. This helps to better understand the course of chronic infections and opens up avenues for new therapies. The findings were published on April 1, 2026, in the journal Immunity.

Original title of the publication: Acute and chronic infections drive distinct trajectories in human memory CD4+ T cell formation
DOI: 10.1016/j.immuni.2026.03.008
Link to the study: https://doi.org/10.1016/j.immuni.2026.03.008

]]> Wed, 17 Jun 2026 10:30:00 +0200 https://fitg8h.podcaster.de/trr179/trr179-new-avenues-for-vaccines-and-cancer-immunotherapies/ pod-0d6c973ae79f8859f673fc75ee9 katrin.woll@med.uni-heidelberg.de (Robert Thimme, Maike Hofmann, Tobias Böttler) Robert Thimme, Maike Hofmann, Tobias Böttler Chronic infections cause long-term changes in key immune cells. T-helper cells suppress their immune function to ensure their survival.

T-helper cells, scientifically known as CD4⁺ T cells, control key processes in our immune system. They detect signs of pathogens and relay signals to other immune cells. In this way, they help B cells produce antibodies and support T killer cells in fighting infected cells. Researchers at the Medical Center – University of Freiburg have now investigated how these immune cells change under prolonged stress during chronic infections. Using chronic hepatitis C infection as an example, the team demonstrated that T helper cells shift their focus: they regulate the immune response less vigorously in order to ensure their own survival. This helps to better understand the course of chronic infections and opens up avenues for new therapies. The findings were published on April 1, 2026, in the journal Immunity.

Original title of the publication: Acute and chronic infections drive distinct trajectories in human memory CD4+ T cell formation
DOI: 10.1016/j.immuni.2026.03.008
Link to the study: https://doi.org/10.1016/j.immuni.2026.03.008

]]> 0 Robert Thimme, Maike Hofmann, Tobias Böttler 0:12:01 TRR179 goes Podcast TRR179 - New avenues for vaccines and cancer immunotherapies T-helper cells, scientifically known as CD4⁺ T cells, control key processes in our immune system. They detect signs of pathogens and relay signals to other immune cells. In this way, they help B cells produce antibodies and support T killer cells in fighting infected cells. Researchers at the Medical Center – University of Freiburg have now investigated how these immune cells change under prolonged stress during chronic infections. Using chronic hepatitis C infection as an example, the team demonstrated that T helper cells shift their focus: they regulate the immune response less vigorously in order to ensure their own survival. This helps to better understand the course of chronic infections and opens up avenues for new therapies. The findings were published on April 1, 2026, in the journal Immunity. Original title of the publication: Acute and chronic infections drive distinct trajectories in human memory CD4+ T cell formation DOI: 10.1016/j.immuni.2026.03.008 Link to the study: https://doi.org/10.1016/j.immuni.2026.03.008 full Welthepatitistag Am 28. Juli 2025 richtete der TRR179 anlässlich des Welt-Hepatitis-Tages an allen drei Standorten Informationsstände zum Thema Hepatitis in den Kliniken ein, um Besucher über Risiken, Symptome, Schutzmaßnahmen und Behandlungsmöglichkeiten von Hepatitis aufzuklären. Experten beantworteten Fragen und stellten Informationen zur Verfügung.

Wir haben Besucher interviewt und hier einen kleinen Ausschnitt der Umfragen an den Standorten zusammengestellt.

]]> Wed, 10 Sep 2025 09:50:00 +0200 https://fitg8h.podcaster.de/trr179/welthepatitistag/ pod-9ef05c3ec73ac8060ff5847756c8 katrin.woll@med.uni-heidelberg.de (TRR179) TRR179 Am 28. Juli 2025 richtete der TRR179 anlässlich des Welt-Hepatitis-Tages an allen drei Standorten Informationsstände zum Thema Hepatitis in den Kliniken ein, um Besucher über Risiken, Symptome, Schutzmaßnahmen und Behandlungsmöglichkeiten von Hepatitis aufzuklären. Experten beantworteten Fragen und stellten Informationen zur Verfügung.

Wir haben Besucher interviewt und hier einen kleinen Ausschnitt der Umfragen an den Standorten zusammengestellt.

]]> 0 TRR179 00:10:42 Welthepatitistag Am 28. Juli 2025 richtete der TRR179 anlässlich des Welt-Hepatitis-Tages an allen drei Standorten Informationsstände zum Thema Hepatitis in den Kliniken ein, um Besucher über Risiken, Symptome, Schutzmaßnahmen und Behandlungsmöglichkeiten von Hepatitis aufzuklären. Experten beantworteten Fragen und stellten Informationen zur Verfügung. Wir haben Besucher interviewt und hier einen kleinen Ausschnitt der Umfragen an den Standorten zusammengestellt. full Hepcludex 2.0 After about 5 years of Hepcludex it´s time to give a follow up on the experiences with the drug. In this episode we talk to the inventor of bulvertide, S. Urban (project leader in our TRR179) and a clinician expert (P. Lampertico from Milan).

We will refer to the following questions:

Which patients benefit from bulevirtide? What about HCC and decomp. cirrhosis?

Do we need interferon for best efficacy? Are the supply chains of interferon a problem?

What do we do with treatment failures? When is someone a treatment failure?

What else is there beyond bulevirtide?

What are the prospects for bulevirtide/entry inhibition in HBV monoinfection?

]]> Thu, 24 Apr 2025 10:46:00 +0200 https://fitg8h.podcaster.de/trr179/hepcludex-20/ pod-9e4677626a3038acf955a4b51298 katrin.woll@med.uni-heidelberg.de (TRR179) TRR179 After about 5 years of Hepcludex it´s time to give a follow up on the experiences with the drug. In this episode we talk to the inventor of bulvertide, S. Urban (project leader in our TRR179) and a clinician expert (P. Lampertico from Milan).

We will refer to the following questions:

Which patients benefit from bulevirtide? What about HCC and decomp. cirrhosis?

Do we need interferon for best efficacy? Are the supply chains of interferon a problem?

What do we do with treatment failures? When is someone a treatment failure?

What else is there beyond bulevirtide?

What are the prospects for bulevirtide/entry inhibition in HBV monoinfection?

]]> 0 TRR179 00:24:55 Hepcludex 2.0 After about 5 years of Hepcludex it´s time to give a follow up on the experiences with the drug. In this episode we talk to the inventor of bulvertide, S. Urban (project leader in our TRR179) and a clinician expert (P. Lampertico from Milan). We will refer to the following questions: Which patients benefit from bulevirtide? What about HCC and decomp. cirrhosis? Do we need interferon for best efficacy? Are the supply chains of interferon a problem? What do we do with treatment failures? When is someone a treatment failure? What else is there beyond bulevirtide? What are the prospects for bulevirtide/entry inhibition in HBV monoinfection? full TRR179 about "Attenuated effector T cells and chronic HBV infection" The authors are refering about the latest paper "Heim, K., Sagar, Sogukpinar, Ö. Sian Llewellyn-Lacey, David A. Price, Florian Emmerich, Anke R. M. Kraft, Markus Cornberg, Sophie Kielbassa, Percy Knolle, Dirk Wohlleber, Bertram Bengsch, Tobias Boettler, Christoph Neumann-Haefelin, Robert Thimme, Maike Hofmann. Attenuated effector T cells are linked to control of chronic HBV infection. Nat Immunol 25, 1650–1662 (2024). https://doi.org/10.1038/s41590-024-01928-4"

]]> Mon, 16 Dec 2024 10:56:00 +0100 https://fitg8h.podcaster.de/trr179/trr179-about-attenuated-effector-t-cells-and-chronic-hbv-infection/ pod-65b68ef64a81765c5341ad7968 katrin.woll@med.uni-heidelberg.de (TRR179) TRR179 The authors are refering about the latest paper "Heim, K., Sagar, Sogukpinar, Ö. Sian Llewellyn-Lacey, David A. Price, Florian Emmerich, Anke R. M. Kraft, Markus Cornberg, Sophie Kielbassa, Percy Knolle, Dirk Wohlleber, Bertram Bengsch, Tobias Boettler, Christoph Neumann-Haefelin, Robert Thimme, Maike Hofmann. Attenuated effector T cells are linked to control of chronic HBV infection. Nat Immunol 25, 1650–1662 (2024). https://doi.org/10.1038/s41590-024-01928-4"

]]> 0 00:09:36 TRR179 about "Attenuated effector T cells and chronic HBV infection" Heim, K., Sagar, Sogukpinar, Ö. Sian Llewellyn-Lacey, David A. Price, Florian Emmerich, Anke R. M. Kraft, Markus Cornberg, Sophie Kielbassa, Percy Knolle, Dirk Wohlleber, Bertram Bengsch, Tobias Boettler, Christoph Neumann-Haefelin, Robert Thimme, Maike Hofmann. Attenuated effector T cells are linked to control of chronic HBV infection. Nat Immunol 25, 1650–1662 (2024). https://doi.org/10.1038/s41590-024-01928-4 full TRR179 and technologies In todays episode we learn about one of our central and service projects, which serves all research projects with their service on experimental and computational single-cell analysis with high spatial resolution.

]]> Wed, 24 Jul 2024 14:53:00 +0200 https://fitg8h.podcaster.de/trr179/trr179-and-technologies/ pod-a7215bf2ca8183d9dcc333ba28 katrin.woll@med.uni-heidelberg.de (TRR179) TRR179 In todays episode we learn about one of our central and service projects, which serves all research projects with their service on experimental and computational single-cell analysis with high spatial resolution.

]]> 0 00:20:48 TRR179 and technologies Use and added value of the technologies in the TRR179 Z03-Project In todays episode we learn about one of our central and service projects, which serves all research projects with their service on experimental and computational single-cell analysis with high spatial resolution. full Opportunities in science and academic research A Podcast of our IRTG together with PIs Ulrike Protzer, Sabrina Schreiner and Marco Binder. Enjoy listening!

]]> Mon, 01 Jul 2024 09:11:00 +0200 https://www.trr179.de/en/graduate-school/ pod-67b7162e70b73eaeea381ded02 katrin.woll@med.uni-heidelberg.de (TRR179) TRR179 A Podcast of our IRTG together with PIs Ulrike Protzer, Sabrina Schreiner and Marco Binder. Enjoy listening!

]]> 0 00:46:41 Opportunities in science and academic research A Podcast of our IRTG together with PIs Ulrike Protzer, Sabrina Schreiner and Marco Binder. Enjoy listening! A Podcast of our IRTG together with PIs Ulrike Protzer, Sabrina Schreiner and Marco Binder. Enjoy listening! full Career Development - Industry In this episode we interview our guests, the two TRR graduates Oliver Grünvogel and Julija Miller together with Peter Wimmer as a successful pharmaceutical manager to get insights about career as researcher in industry.

]]> Wed, 03 Jan 2024 11:13:00 +0100 https://fitg8h.podcaster.de/trr179/career-development-industry/ pod-8379b9e89238886ae78e69d6d4 katrin.woll@med.uni-heidelberg.de (TRR179) TRR179 In this episode we interview our guests, the two TRR graduates Oliver Grünvogel and Julija Miller together with Peter Wimmer as a successful pharmaceutical manager to get insights about career as researcher in industry.

]]> 0 TRR179 00:42:00 TRR179 goes Podcast Career Development - Industry In this episode we interview our guests, the two TRR graduates Oliver Grünvogel and Julija Miller together with Peter Wimmer as a successful pharmaceutical manager to get insights about career as researcher in industry. full Therapeutic Vaccination against HBV Key factor for successful therapeutic vaccination against chronic hepatitis B identified: Our colleagues in Munich found that the success of therapeutic hepatitis B vaccination depends on efficient priming of HBV-specific CD4 T cells. The results have been published in the Journal of Hepatology.

]]> Wed, 12 Apr 2023 15:51:00 +0200 https://fitg8h.podcaster.de/trr179/therapeutic-vaccination-against-hbv/ pod-d8077c5f4ac3c718d7a8752c46 katrin.woll@med.uni-heidelberg.de (TRR179) TRR179 Key factor for successful therapeutic vaccination against chronic hepatitis B identified: Our colleagues in Munich found that the success of therapeutic hepatitis B vaccination depends on efficient priming of HBV-specific CD4 T cells. The results have been published in the Journal of Hepatology.

]]> 0 00:14:06 Therapeutic Vaccination against HBV Key factor for successful therapeutic vaccination against chronic hepatitis B identified: Our colleagues in Munich found that the success of therapeutic hepatitis B vaccination depends on efficient priming of HBV-specific CD4 T cells. The results have been published in the Journal of Hepatology. full TRR179 Juniors - our IRTG In today's episode, our PhD- and MD-students present the integrated graduate school of the TRR. A very varied and informative compilation. Enjoy listening!

]]> Tue, 04 Oct 2022 09:48:00 +0200 https://fitg8h.podcaster.de/trr179/trr179-juniors-our-irtg/ pod-8af4e9dd9c811960332612676b katrin.woll@med.uni-heidelberg.de (TRR179) TRR179 In today's episode, our PhD- and MD-students present the integrated graduate school of the TRR. A very varied and informative compilation. Enjoy listening!

]]> 0 IRTG TRR179 00:10:37 In today's episode, our PhD- and MD-students present the integrated graduate school of the TRR. A very varied and informative compilation. Enjoy listening! full TRR179 Conference The 5th Podcast is a very special edition which gives an impression and snapshots of the international conference, which took place from 29-31.5.2022 in Freiburg. Listen to wraps ups of the highlights of some of our invited speakers ...and feel the spirit of the international research community in the field of viral hepatitis and beyond.

]]> Fri, 10 Jun 2022 10:21:00 +0200 http://www.trr179.de/en/news/conference/ pod-6c38d78ce9127164d27fb1aae7 katrin.woll@med.uni-heidelberg.de (TRR179) TRR179 The 5th Podcast is a very special edition which gives an impression and snapshots of the international conference, which took place from 29-31.5.2022 in Freiburg. Listen to wraps ups of the highlights of some of our invited speakers ...and feel the spirit of the international research community in the field of viral hepatitis and beyond.

]]> 0 00:13:32 The 5th Podcast is a very special edition which gives an impression and snapshots of the international conference, which took place from 29-31.5.2022 in Freiburg. Listen to wraps ups of the highlights of some of our invited speakers ...and feel the spirit of the international research community in the field of viral hepatitis and beyond. full TRR179: Auto-aggressive T-Zellen Heute ist Tobias im Gespräch mit einem unserer Projektleiter, Percy Knolle, und seinem PostDoc Michael Dudek. Sie unterhalten sich über die neusten Erkenntnisse zu auto-aggressiven T-Zellen und Autoimmunität in NASH. Das hat auch Implikation für die gesamte Bandbreite der Virushepatitis.

Shownotes:

Dudek, M., Pfister, D., Donakonda, S. et al. Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH. Nature 592, 444–449 (2021)“

TRR179 Determinants and dynamics of elimination versus persistence of hepatitis virus infection | Science | Publications

Mehr zu unserer Forschung erfahrt Ihr auch auf der Konfernz in Freiburg am 30./31.5.2022: TRR179 Determinants and dynamics of elimination versus persistence of hepatitis virus infection | News | SAVE THE DATE 30/31.5.2022.

Wir freuen uns auf Euren Besuch, die Teilnahme ist kostenfrei!

]]> Mon, 14 Feb 2022 13:42:00 +0100 https://fitg8h.podcaster.de/trr179/trr179-auto-aggressive-t-zellen/ pod-a9b1dc34ce31f2d3b22e0d58a4 katrin.woll@med.uni-heidelberg.de (TRR179) TRR179 Heute ist Tobias im Gespräch mit einem unserer Projektleiter, Percy Knolle, und seinem PostDoc Michael Dudek. Sie unterhalten sich über die neusten Erkenntnisse zu auto-aggressiven T-Zellen und Autoimmunität in NASH. Das hat auch Implikation für die gesamte Bandbreite der Virushepatitis.

Shownotes:

Dudek, M., Pfister, D., Donakonda, S. et al. Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH. Nature 592, 444–449 (2021)“

TRR179 Determinants and dynamics of elimination versus persistence of hepatitis virus infection | Science | Publications

Mehr zu unserer Forschung erfahrt Ihr auch auf der Konfernz in Freiburg am 30./31.5.2022: TRR179 Determinants and dynamics of elimination versus persistence of hepatitis virus infection | News | SAVE THE DATE 30/31.5.2022.

Wir freuen uns auf Euren Besuch, die Teilnahme ist kostenfrei!

]]> 0 TRR179 00:15:58 TRR179: Auto-aggressive T-Zellen Was autoaggressive T-Zellen böses anrichten können und was wir daraus für die Virushepatitis erkennen Heute ist Tobias im Gespräch mit einem unserer Projektleiter, Percy Knolle, und seinem PostDoc Michael Dudek. Sie unterhalten sich über die neusten Erkenntnisse zu autoaggressiven T-Zellen und Autoimmunität in NASH. Das hat auch Implikation für die gesamte Bandbreite der Virushepatitis. 4 full 1 TRR179 and "Hepcludex" Heute ist Tobias im Gespräch mit Stephan Urban, Teilprojektleiter des TRR179, der im Rahmen seiner Forschung das Medikament zur Behandlung von Hepatitis D entdeckt hat.

Shownotes:

Erstes Medikament gegen Hepatitis D von der Europäischen Kommission zugelassen (uni-heidelberg.de)

TRR179 Determinants and dynamics of elimination versus persistence of hepatitis virus infection

Universitätsklinikum Heidelberg: Molecular Virology (uni-heidelberg.de)

Urban S, Neumann-Haefelin C, Lampertico P Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease Gut 2021;70:1782-1794.

]]> Fri, 22 Oct 2021 13:23:00 +0200 https://fitg8h.podcaster.de/trr179/trr179-and-hepcludex/ pod-59d0e07f764222b6a957792dc2 katrin.woll@med.uni-heidelberg.de (TRR179) TRR179 Heute ist Tobias im Gespräch mit Stephan Urban, Teilprojektleiter des TRR179, der im Rahmen seiner Forschung das Medikament zur Behandlung von Hepatitis D entdeckt hat.

Shownotes:

Erstes Medikament gegen Hepatitis D von der Europäischen Kommission zugelassen (uni-heidelberg.de)

TRR179 Determinants and dynamics of elimination versus persistence of hepatitis virus infection

Universitätsklinikum Heidelberg: Molecular Virology (uni-heidelberg.de)

Urban S, Neumann-Haefelin C, Lampertico P Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease Gut 2021;70:1782-1794.

]]> 0 00:29:02 TRR179 and "Hepcludex" Today in discussion with Stephan Urban about "Hepcludex" Heute ist Tobias im Gespräch mit Stephan Urban, Teilprojektleiter des TRR179, der im Rahmen seiner Forschung das Medikament zur Behandlung von Hepatitis D entdeckt hat. 3 full 1 TRR179 and SARS-CoV-2 Hört euch an, wie wir unsere bisherige Forschungsexpertise an Hepatitisviren zur Erforschung von SARS-Co-V einsetzen können!

fyyd: TRR179: TRR179 and SARS-CoV-2

Shownotes:

TRR179 (@TRR179_2) / Twitter

The Binder Lab (@TheBinderLab) / Twitter

www.trr179.de

]]> Tue, 06 Jul 2021 12:35:18 +0200 https://fitg8h.podcaster.de/trr179/trr179-and-sars-cov-2/ pod-6429d38596e5aced916a8e0a38 katrin.woll@med.uni-heidelberg.de (TRR179) TRR179 Hört euch an, wie wir unsere bisherige Forschungsexpertise an Hepatitisviren zur Erforschung von SARS-Co-V einsetzen können!

fyyd: TRR179: TRR179 and SARS-CoV-2

Shownotes:

TRR179 (@TRR179_2) / Twitter

The Binder Lab (@TheBinderLab) / Twitter

www.trr179.de

]]> 0 TRR179 00:20:06 TRR179 and SARS-CoV-2 Hört euch an, wie wir unsere bisherige Forschungsexpertise an Hepatitisviren zur Erforschung von SARS-Co-V einsetzen können! Hört euch an, wie wir unsere bisherige Forschungsexpertise zur Erforschung von SARS-Co-V einsetzen können! Neues aus der Welt der Viren, Proteine, Interferone und Immunantwort... 2 full 1 TRR179 goes Podcast We hope you enjoy getting new insights an information about Hepatits C Virus research ]]> Fri, 07 May 2021 13:59:12 +0200 http://www.trr179.de/en/ pod-60952b45d0912477518962 katrin.woll@med.uni-heidelberg.de (katrin.woll@med.uni-heidelberg.de (TRR179)) katrin.woll@med.uni-heidelberg.de (TRR179) We hope you enjoy getting new insights an information about Hepatits C Virus research ]]> 0 TRR179 00:12:39 TRR179 No1 Podcast More about Hepatitis C and virus research of our consortium This is the FIRST Podcast of the TRR179! We hope you enjoy getting new insights an information about Hepatits C Virus research 1 full 1